Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...
Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching US$ 0.81 Billion in ...
- LabConnect anuncia la formación de un Consejo Asesor Estratégico y el nombramiento de sus miembros inaugurales Personalised advertising and content, advertising and content measurement, audience ...
LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its ...
La farmacéutica Merck anunció el jueves que tiene previsto interrumpir anticipadamente un estudio de fase avanzada de su fármaco contra la hipertensión arterial pulmonar (HAP) ...
Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rating on Surrozen (SRZN).Invest with Confidence: Follow TipRanks' ...
Los demócratas del Senado recuerdan al elegido por Trump para secretario de Salud su insistente postura crítica contra la ...
Su prima, Caroline Kennedy, lo tacha de “depredador” y dice que se llegó a deleitar con una “escena perversa de desesperación ...
El diseñador de chips cede un 1,44% tras haberse hundido un 17% en la sesión del lunes. Más información: La amenaza china de ...
Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback